Partnering to push the boundaries of science
London – We have been collaborating together for around five years to identify and validate novel therapeutic targets for NASH, a chronic liver disease which can have serious, life-threatening consequences.
Our recent high impact publication in Nature Metabolism reports exciting results from this research with the identification of PSD3, a new genetic target that has been shown to be associated with fatty liver disease.1 This is an important discovery which may lead to the development of a future treatment of NASH.
Cases of NAFLD and its more serious variant NASH are on the rise, but therapeutic options remain limited.2,3 Fat accumulation in the liver can lead to chronic liver disease with potentially life-threatening complications, including cirrhosis and liver cancer, as well as obesity, type 2 diabetes, and chronic kidney disease.4
NASH is a complex disease with multiple drivers, including strong genetic factors.2 Our early research has focused on identifying genetic targets in order to develop tailored therapies for this disease.